JB Chemicals & Pharmaceuticals

Torrent Pharma market capitalisation stood at ₹1.28 trillion on Monday, while that of Cipla at ₹1.22 trillion, shows BSE.

Fair trade regulator CCI on Tuesday cleared Torrent Pharmaceuticals Ltd's proposed acquisition of a stake in JB Chemicals and Pharmaceuticals, subject to voluntary modifications offered by the companies. The development came after Torrent Pharmaceuticals in June this year announced the acquisition of a majority stake in JB Chemicals and Pharmaceuticals in a Rs 19,500-crore deal. "The proposed combination relates to the acquisition of shareholding by Torrent Pharmaceuticals Ltd (acquirer) in JB Chemicals & Pharmaceuticals Ltd (target) and the subsequent amalgamation of the target with the acquirer," the regulator said in a release. After the completion of the deal, Torrent Pharmaceuticals will become India's second most valued pharma company. "The Commission approved the proposed combination subject to compliance with voluntary modifications offered by the parties (Torrent Pharmaceuticals Ltd and JB Chemicals & Pharmaceuticals Ltd)," it added. Torrent Pharmaceuticals is the ...

JB Chemicals & Pharmaceuticals Ltd on Wednesday reported a 14 per cent rise in net profit to Rs 202 crore in the June quarter. The company had posted a net profit of Rs 177 crore in the corresponding period of the previous fiscal year, JB Chemicals & Pharmaceuticals (JB Pharma) said in a regulatory filing. Revenue in the first quarter stood at Rs 1,094 crore as against Rs 1,004 crore in the same period a year ago, up 9 per cent, it added. "The domestic business recorded approximately 14 per cent value growth. This was driven by acute and chronic segments, including our ophthalmology portfolio. Our major brands & their franchises are also performing well," JB Pharma CEO and Wholetime Director, Nikhil Chopra said. He further said, "The CDMO (contract development and manufacturing organisation) business momentum is likely to sustain in coming quarters." The company said its domestic formulations business recorded revenue of Rs 678 crore as against Rs 595 crore in the first ...

Ahmedabad-based Torrent Pharmaceuticals has sought fair trade regulator CCI's clearance to acquire a majority stake in in J B Chemicals and Pharmaceuticals in a Rs 19,500-crore deal. After the completion of the deal, Torrent Pharmaceuticals will become India's second most valued pharma company. The development came after Torrent Pharmaceuticals in June this year announced the acquisition of a majority stake in J B Chemicals and Pharmaceuticals in a Rs 19,500-crore deal. "The proposed combination relates to acquisition of shareholding by the acquirer (Torrent Pharmaceuticals Ltd) in the target (J B Chemicals & Pharmaceuticals Ltd) and the subsequent amalgamation of the target with the acquirer," according to a notice filed with the Competition Commission of India (CCI). Torrent Pharmaceuticals is the flagship company of the Torrent group and is engaged in the business of manufacturing and sale of pharmaceutical formulations (FDFs) across therapeutic segments. J B Chemicals & ...

Torrent is acquiring a 46.39 per cent stake in JB Chemicals from KKR & Co. for about ₹11,917 crore, and an additional 2.8 per cent stake from employees for roughly ₹719 crore, both at ₹1,600 per share

Torrent Pharmaceuticals has signed a definitive agreement to acquire a controlling stake in JB Chemicals and Pharmaceuticals (JBCP) at a fully diluted equity valuation of ₹25,689 crore.

Torrent Pharma is negotiating to acquire JB Chemicals from KKR in a deal that may trigger an open offer, strengthening its position in the domestic pharma market

In the previous trading session, Sensex gained 182.34 points, or 0.22 per cent, to settle at 81,330.56 level. The Nifty50, meanwhile, closed 88.55 points, or 0.36 per cent higher at 24,666.90 level.

JB Pharma posts strong FY25 performance with 19.3% profit growth; domestic business up 20%, CDMO segment and Russia drive international gains

Tausif Shaikh, India analyst for pharma and healthcare, BNP Paribas India, prefers domestic-focused companies like Torrent Pharmaceuticals, and JB Chemicals and Pharmaceuticals in the sector

Reports suggested that promoter Tau Investment Holdings Pte was likely to sell a 10.2 per cent stake in the company through block deals

The decline in pharma stocks followed comments from President Donald Trump, who indicated that the US may impose tariffs of around 25 per cent on pharmaceutical, automobile, and semiconductor imports

Stocks such as Natco, Dr. Reddy's, Cipla, Mankind, Torrent, Sun Pharma, Abbott, and Glenmark slipped in the range of 1-2 per cent

Gross margins stood at 67.1 per cent for Q3FY25 and 66.5 per cent for 9M FY25

Individually, Cipla soared up to 3.68 per cent to hit an intraday high of Rs 1,547.70 per share, while Sun Pharma soared up to 3.30 per cent to hit an intraday high of Rs 1,791.60 per share

JB Pharma is on track to deliver strong results in the second half of financial year 2024-25

The company stated it has a strong order book for the remaining quarters of this financial year

Deliberations about the stake purchase are ongoing and no final decisions have been made, the people said. Other bidders may still remain interested in acquiring the stake, the people said

Company crosses Rs 1,000 crore quarterly revenue mark

JB Chemicals & Pharmaceuticals on Thursday said its net profit increased 25 per cent year-on-year to Rs 177 crore in the first quarter ended June 30, 2024. The drug firm had reported a net profit of Rs 142 crore in the April-June period last fiscal. Total income increased to Rs 1,010 crore in the June quarter from Rs 902 crore in the year-ago period, JB Pharma said in a regulatory filing. "Our overall performance in the first quarter has been robust. We have reached a new milestone of Rs 1,000 crore in quarterly sales for the first time during any quarter, with improvement across all parameters - revenue, gross profit, operating profit and operating profit margin," CEO and Wholetime Director Nikhil Chopra stated. Strong performance in the domestic business has continued, with each of the big brand franchises witnessing market-beating growth, he added. "We expect the international business including CDMO business to pick up in the second half of the financial year. The good start .